US FDA is holding a public workshop in November to discuss challenges and best practices with the development of cardiac troponin assays. The Nov. 28 meeting at the agency's Silver Spring, Md., headquarters is intended to "facilitate device development and to discuss scientific and regulatory challenges associated with the analytical and clinical validation methods for troponin assay devices," FDA said in a federal register notice announcing the meeting.
Troponin is a protein which if found in high amounts in the blood could signal heart muscle death and predict a heart attack
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?